RURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

RURUS SURYAWAN评分:一种预测接受直接经皮冠状动脉介入治疗的急性心肌梗死患者30天死亡率的新型评分系统

阅读:2

Abstract

Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Due to an inconsistent result about predictors of 30-day outcomes regarding scoring systems for the first episode of acute myocardial infarction, the objective of this study is to develop novel scoring systems to predict 30-day mortality among patients with a first episode of acute myocardial infarction who underwent primary percutaneous coronary intervention. Methods: This retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction who underwent primary percutaneous coronary intervention between 2021 and 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling and collected 1714 patients, of which 1535 patients were included. Our primary outcomes included 30-day mortality. Results: The analysis included 1535 patients: 926 in the derivation set and 609 in the validation set. In our study, the 30-day mortality rate was 20.7%. Multivariate logistic regression analysis was used to build prediction models in the derivation group and then validated in the validation cohort. The area under the ROC curve of the RURUS SURYAWAN score to predict 30-day mortality was 0.944 (0.906-0.972) in the derivation set and 0.959 (0.921-0.983) in the validation set, with 94.6% sensitivity and 97.3% specificity (p < 0.001). Conclusions: After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictors of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。